Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

What are Estimates?01:06

What are Estimates?

9.3K
It isn't easy to measure a parameter such as the mean height or the mean weight of a population. So, we draw samples from the population and calculate the mean height or mean weight of the individuals in the sample. This sample data acts as a representative measure of the population parameter. These sample statistics are known as estimates. 
The estimate for the mean of a sample is denoted by ͞x, whereas the mean of the population is designated as μ. Further, parameters such...
9.3K
Pharmacodynamic Models: Additive and Proportional Drug Effect Model01:09

Pharmacodynamic Models: Additive and Proportional Drug Effect Model

91
Drug response models describe how pharmacological agents interact with biological systems to produce measurable effects. Baseline responses are inherent physiological activities without a drug significantly influencing the observed pharmacological outcomes. Depending on the drug response model employed, these baseline responses may combine with the drug's effect in either an additive or proportional manner.Additive Drug Response ModelIn the additive model, the drug effect is independent of the...
91
Pharmacokinetic Models: Comparison and Selection Criterion01:26

Pharmacokinetic Models: Comparison and Selection Criterion

464
Physiological and compartmental models are valuable tools used in studying biological systems. These models rely on differential equations to maintain mass balance within the system, ensuring an accurate representation of the dynamic processes at play.
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
464
Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches01:14

Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches

684
Drug disposition in the body is a complex process and can be studied using two major approaches: the model and the model-independent approaches.
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...
684
Analysis of Population Pharmacokinetic Data01:12

Analysis of Population Pharmacokinetic Data

952
Analysis of population pharmacokinetic data involves studying the behavior of drugs within diverse populations to understand their pharmacokinetic parameters. Traditional pharmacokinetic methods typically involve collecting samples from a few individuals and estimating these parameters. While these methods are commonly used, they have limitations in capturing the variability in drug response among individuals or heterogeneous populations. Population pharmacokinetics is employed to address these...
952
Model Approaches for Pharmacokinetic Data: Distributed Parameter Models01:06

Model Approaches for Pharmacokinetic Data: Distributed Parameter Models

317
Pharmacokinetic models are mathematical constructs that represent and predict the time course of drug concentrations in the body, providing meaningful pharmacokinetic parameters. These models are categorized into compartment, physiological, and distributed parameter models.
The distributed parameter models are specifically designed to account for variations and differences in some drug classes. This model is particularly useful for assessing regional concentrations of anticancer or...
317

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Assessing Covariate Clinical Relevance in High-Dimensional PK Analysis: A Comparison of SCM+, FFEM, and FREM Approaches.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Advances and Further Comparison of Software Tools for Fisher Information Matrix-Based Design Evaluation in Pharmacometrics.

Pharmaceutical research·2026
Same author

Conditional Versus Unconditional Covariate Effects in Pharmacometric Models: Implications for Interpretation, Communication, and Reporting.

CPT: pharmacometrics & systems pharmacology·2026
Same author

Exposure-Response Analysis for Time-to-Event Data in the Presence of Adaptive Dosing: Efficient Approaches and Pitfalls.

CPT: pharmacometrics & systems pharmacology·2025
Same author

Impact of covariate model building methods on their clinical relevance evaluation in population pharmacokinetic analyses: comparison of the full model, stepwise covariate model (SCM) and SCM+  approaches - further results based on more conventional practices.

Journal of pharmacokinetics and pharmacodynamics·2025
Same author

A Pharmacometrics-Informed Trial Simulation Framework for Optimizing Study Designs for Disease-Modifying Treatments in Rare Neurological Disorders.

CPT: pharmacometrics & systems pharmacology·2025
Same journal

Best Practices in Physiologically Based Pharmacokinetic (PBPK) Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Integrated Population Pharmacokinetic Analysis of Intravitreal Aflibercept Drug Products.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Development and Use of a Population Pharmacokinetic Model for Characterizing the Pharmacokinetics of Vonoprazan in Pediatric Patients.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

A Narrative Review of Artificial Intelligence for Drug Repurposing: Lessons From COVID-19 and Oncology (2020-2025).

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Butorphanol Pharmacokinetics Across Species: Meta-Analysis Integrating Allometric Scaling and Minimal Physiologically Based Pharmacokinetic Modeling.

CPT: pharmacometrics & systems pharmacology·2026
Same journal

Accelerating Subcutaneous Drug Development: A Mechanistic Absorption Model for the Open Systems Pharmacology Framework.

CPT: pharmacometrics & systems pharmacology·2026
See all related articles

Related Experiment Video

Updated: Apr 15, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.5K

Objective First, Method Second: Why the Estimand Definition Comes First in Pharmacometric Covariate Modeling.

E Niclas Jonsson1, Joakim Nyberg1, France Mentré2

  • 1Pharmetheus AB, Uppsala, Sweden.

CPT: Pharmacometrics & Systems Pharmacology
|April 14, 2026
PubMed
Summary
This summary is machine-generated.

Pharmacometric covariate analyses serve distinct goals: mechanistic insight and clinical decisions. The ICH E9(R1) estimand framework clarifies these objectives, guiding covariate modeling for better patient care.

Keywords:
covariatesestimandmodel communicationpharmacometrics

More Related Videos

An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.8K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.1K

Related Experiment Videos

Last Updated: Apr 15, 2026

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index
06:55

Inverse Probability of Treatment Weighting Propensity Score using the Military Health System Data Repository and National Death Index

Published on: January 8, 2020

15.5K
An R-Based Landscape Validation of a Competing Risk Model
05:37

An R-Based Landscape Validation of a Competing Risk Model

Published on: September 16, 2022

2.8K
Establishing a Competing Risk Regression Nomogram Model for Survival Data
04:57

Establishing a Competing Risk Regression Nomogram Model for Survival Data

Published on: October 23, 2020

11.1K

Area of Science:

  • Pharmacometrics
  • Quantitative Pharmacology
  • Clinical Pharmacology

Background:

  • Pharmacometric covariate analyses are crucial for understanding drug behavior and informing clinical decisions.
  • Two primary objectives exist: mechanistic understanding and clinical decision-making, each requiring different analytical approaches.
  • The distinction between these objectives and their analytical targets has historically been unclear.

Purpose of the Study:

  • To clarify the distinct objectives of pharmacometric covariate analyses.
  • To reconcile mechanistic modeling with regulatory and clinical needs using a structured framework.
  • To emphasize the importance of estimand definition in covariate modeling.

Main Methods:

  • Adoption of the International Council for Harmonisation E9(R1) estimand framework.
  • Distinguishing between conditional covariate effects (mechanistic) and unconditional covariate effects (clinical/regulatory).
  • Prioritizing estimand definition (the objective) over the estimator in covariate modeling.

Main Results:

  • The ICH E9(R1) estimand framework provides a clear distinction between mechanistic and clinical objectives in covariate analyses.
  • This framework reconciles the differing needs of mechanistic modeling and regulatory/clinical decision-making.
  • Estimand definition is identified as the primary choice in covariate modeling, not the specific estimation method.

Conclusions:

  • A structured approach using the ICH E9(R1) estimand framework optimizes pharmacometric covariate analyses.
  • This approach enhances the quantitative evidence used for communicating clinical impact.
  • Clear estimand definition leads to improved patient care through better-informed clinical decisions.